LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone

Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib manage symptoms but do not substantially change the natural history of the disease. In this report, we show the effects of IMG-7289...

Descripción completa

Detalles Bibliográficos
Autores principales: Jutzi, Jonas S., Kleppe, Maria, Dias, Jennifer, Staehle, Hans Felix, Shank, Kaitlyn, Teruya-Feldstein, Julie, Gambheer, Sudheer Madan Mohan, Dierks, Christine, Rienhoff, Hugh Y., Levine, Ross L., Pahl, Heike L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745991/
https://www.ncbi.nlm.nih.gov/pubmed/31723778
http://dx.doi.org/10.1097/HS9.0000000000000054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745991/
https://www.ncbi.nlm.nih.gov/pubmed/31723778
http://dx.doi.org/10.1097/HS9.0000000000000054

Ejemplares similares